AR070352A1 - Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. - Google Patents
Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto.Info
- Publication number
- AR070352A1 AR070352A1 ARP090100424A ARP090100424A AR070352A1 AR 070352 A1 AR070352 A1 AR 070352A1 AR P090100424 A ARP090100424 A AR P090100424A AR P090100424 A ARP090100424 A AR P090100424A AR 070352 A1 AR070352 A1 AR 070352A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- preventive
- composition
- heteroaryl
- Prior art date
Links
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title abstract 2
- 108091007960 PI3Ks Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000732 arylene group Chemical group 0.000 abstract 2
- 125000005549 heteroarylene group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
Abstract
Se proporciona un agente preventivo o terapéutico de una enfermedad proliferativa, tal como el cáncer, que tiene efectos inhibidores de la enzima PI3K de características superiores, una accion inhibidora de la proliferacion celular superior, al igual que una mejorada estabilidad en el organismo e hidrosolubilidad. Reivindicacion 1: Un compuesto representado por la formula (1) caracterizado porque Q representa un grupo ligador representado por -X-Y-; X representa un enlace simple, -CO-, -CONH-, -CONalquilo C1-4-, -CS-, -CSNH-, -CSNalquilo C1-4- o -SO2-; Y representa un enlace simple, arileno o heteroarileno (el arileno y el heteroarileno pueden estar insustituidos o sustituidos en las posiciones 1 a 4 por -halogeno, -alquilo C1-6, -OH o -Oalquilo C1-6; siempre que X e Y no sean simultáneamente enlaces simples; R1 representa -alquileno C0-6-(A)m-alquilo C1-6, o alquileno C0-6-(A)m-alquileno C0-6-(heterociclo); A representa -CO-, -CS-, -CONH-, -CONalquilo C1-4-, -CSNH-, - CSNalquilo C1-4-, -NH- o -Nalquilo C1-4-; m representa 0 o 1; el mencionado -(heterociclo) es heteroarilo, o un grupo representado por la formula (2), donde Ra y Rb son iguales o diferentes y representan un átomo de hidrogeno, -alquilo C1-6, -halogeno, -OH o -Oalquilo C1-6; W representa -CRcRd-, -O-, -S-, -SO-, SO2 o -NRe-; n representa 0 o 1; Rc y Rd son iguales o diferentes y representan un átomo de hidrogeno, -halogeno, -alquilo C1-6, -OH, -Oalquilo C1-6 o heteroarilo; Re representa un átomo de hidrogeno, -alquilo C1-6, -OH, -Oalquilo C1-6 o heteroarilo (-alquilo C1-6 y -Oalquilo C1-6 en Rc, Rd y Re pueden estar sustituidos por -halogeno o -OH), o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008027423 | 2008-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070352A1 true AR070352A1 (es) | 2010-03-31 |
Family
ID=40952235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100424A AR070352A1 (es) | 2008-02-07 | 2009-02-06 | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100324284A1 (es) |
| EP (1) | EP2239261A4 (es) |
| JP (1) | JP5350277B2 (es) |
| KR (1) | KR20100120680A (es) |
| CN (1) | CN101932584A (es) |
| AR (1) | AR070352A1 (es) |
| AU (1) | AU2009211622A1 (es) |
| BR (1) | BRPI0907931A2 (es) |
| CA (1) | CA2711778A1 (es) |
| CL (1) | CL2009000241A1 (es) |
| IL (1) | IL207452A0 (es) |
| MX (1) | MX2010008686A (es) |
| PE (1) | PE20091486A1 (es) |
| TW (1) | TW200938201A (es) |
| WO (1) | WO2009099163A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2209786B1 (en) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| AU2009314544C1 (en) * | 2008-11-11 | 2015-11-12 | Xcovery Holding Company Llc | PI3K/mTOR kinase inhibitors |
| TW201038567A (en) | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| WO2010114484A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| CA2905123A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| CN104557872B (zh) * | 2013-10-16 | 2017-05-24 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| ES2727374T3 (es) | 2014-04-04 | 2019-10-15 | Crown Bioscience Inc Taicang | Gen de fusión HNF4G-RSPO2 |
| ES2877799T3 (es) * | 2015-12-31 | 2021-11-17 | Shanghai Pharmaceuticals Holding Co Ltd | Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones |
| US10822336B2 (en) * | 2016-09-29 | 2020-11-03 | Daiichi Sankyo Company, Limited | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
| IT201800004082A1 (it) * | 2018-03-29 | 2019-09-29 | Berlin Chemie Ag | Composizioni farmaceutiche antitumorali per terapia combinata |
| CN113200969B (zh) * | 2021-05-19 | 2022-11-25 | 中国药科大学 | 一种PI3Kα选择性抑制剂及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2067221C (en) | 1989-10-11 | 1997-04-15 | Yasuji Sakuma | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
| ES2150941T3 (es) * | 1992-04-03 | 2000-12-16 | Upjohn Co | Aminas biciclicas-heterociclicas eficaces farmaceuticamente. |
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| KR100774855B1 (ko) * | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| GB0100622D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| EA200801968A1 (ru) * | 2006-03-11 | 2009-02-27 | Вернэлис (Р&Д) Лтд. | Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90 |
| EP2050749B1 (en) * | 2006-08-08 | 2017-11-22 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivative as pi3k inhibitor and use thereof |
-
2009
- 2009-02-04 CL CL2009000241A patent/CL2009000241A1/es unknown
- 2009-02-04 TW TW098103461A patent/TW200938201A/zh unknown
- 2009-02-05 PE PE2009000176A patent/PE20091486A1/es not_active Application Discontinuation
- 2009-02-06 EP EP09707958A patent/EP2239261A4/en not_active Withdrawn
- 2009-02-06 AU AU2009211622A patent/AU2009211622A1/en not_active Abandoned
- 2009-02-06 BR BRPI0907931-9A patent/BRPI0907931A2/pt not_active IP Right Cessation
- 2009-02-06 US US12/735,656 patent/US20100324284A1/en not_active Abandoned
- 2009-02-06 WO PCT/JP2009/052017 patent/WO2009099163A1/ja not_active Ceased
- 2009-02-06 KR KR1020107019767A patent/KR20100120680A/ko not_active Withdrawn
- 2009-02-06 MX MX2010008686A patent/MX2010008686A/es active IP Right Grant
- 2009-02-06 CN CN2009801039716A patent/CN101932584A/zh active Pending
- 2009-02-06 JP JP2009552523A patent/JP5350277B2/ja not_active Expired - Fee Related
- 2009-02-06 CA CA2711778A patent/CA2711778A1/en not_active Abandoned
- 2009-02-06 AR ARP090100424A patent/AR070352A1/es not_active Application Discontinuation
-
2010
- 2010-08-05 IL IL207452A patent/IL207452A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2009099163A1 (ja) | 2011-05-26 |
| IL207452A0 (en) | 2010-12-30 |
| PE20091486A1 (es) | 2009-10-14 |
| US20100324284A1 (en) | 2010-12-23 |
| WO2009099163A1 (ja) | 2009-08-13 |
| CN101932584A (zh) | 2010-12-29 |
| CL2009000241A1 (es) | 2010-09-03 |
| EP2239261A1 (en) | 2010-10-13 |
| AU2009211622A1 (en) | 2009-08-13 |
| JP5350277B2 (ja) | 2013-11-27 |
| TW200938201A (en) | 2009-09-16 |
| CA2711778A1 (en) | 2009-08-13 |
| BRPI0907931A2 (pt) | 2015-07-28 |
| KR20100120680A (ko) | 2010-11-16 |
| MX2010008686A (es) | 2010-08-30 |
| EP2239261A4 (en) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| PA8813101A1 (es) | Derivados bicílicos de carboxamidas aza-bicíclicas,su preparación y su aplicación terapéutica | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
| MX378717B (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR076360A1 (es) | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| BR112017009583A2 (pt) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 | |
| TN2015000005A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| MX2020005738A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| BR112017000584A2 (pt) | inibidores da aldosterona sintase | |
| ECSP088257A (es) | Derivados de amida | |
| AR086803A1 (es) | Derivados de oxazetidinas, composiciones farmaceuticas y cosmeticas que los contienen y uso de los mismos para tratar enfermedades dermatologicas fundamentalmente, y del aparato respiratorio, digestivo y cardiovascular, entre otras | |
| AR073842A1 (es) | Derivados del acido 4- dimetilaminobutirico , proceso para su preparacion , composiciones farmacéuticas y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |